Co-Amoxiclav Administration Safety Guidelines

Special Population Considerations

• The American Geriatrics Society recommends using co-amoxiclav with caution in elderly patients (>65 years) and considering high-dose formulations (875 mg/125 mg twice daily or 2000 mg/125 mg twice daily) for respiratory infections, with a strength of evidence based on clinical guidelines 1
• The American College of Gastroenterology recommends that amoxicillin-clavulanic acid is safe and can be administered during pregnancy for conditions such as pouchitis, perianal Crohn's disease, or intra-abdominal abscesses in pregnant patients with inflammatory bowel disease, with a moderate level of evidence 2

Clinical Response Evaluation

• The Infectious Diseases Society of America recommends evaluating clinical response within 48-72 hours of initiating co-amoxiclav therapy to determine the need for alternative management, with a high level of evidence based on clinical trials 3, 1

Drug Interactions

• The American Heart Association recommends monitoring INR in anticoagulated patients taking co-amoxiclav due to potential interactions with warfarin and other medications, with a moderate level of evidence based on clinical studies 4